Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ERN1 | O75460 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604322 | 0.90 | TDP1 (0.43) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL1808858 | 0.90 | TDP1 (0.48) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL31618920 | 0.88 | TDP1 (0.41) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL1972414 | 0.88 | TDP1 (0.41) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL248719 | 0.84 | ERN1 (0.50) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL6187165 | 0.83 | TDP1 (0.46) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL8332206 | 0.82 | PTPN1 (0.44) | TDP1ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL1057387 | 0.82 | ERN1 (0.44) | TDP1ERN1 | |
| SCHEMBL16396120 | 0.82 | ERN1 (0.41) | TDP1ERN1ALDH1A1LMNA | |
| SCHEMBL27871969 | 0.82 | GAA (0.44) | TDP1ERN1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115720578-B | And tricyclic derivatives, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240228494-A1 | COMPOUNDS | Pathios Therapeutics Limited (GB) | 2024-07-11 | — | — | US | disclosed |
| EP-4330258-A1 | COMPOUNDS | Pathios Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| CN-115720578-A | Tricyclic derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-19 | — | — | US | disclosed |
| US-9108903-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2014120820-A9 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014120820-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2334657-B1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-2334657-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228494-A1 | COMPOUNDS | NR1H4, NR1H2, NR1H3 | TDP1 3872/4885ERN1 1796/4885ALDH1A1 858/4885 |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | TDP1 3674/4885ERN1 2993/4885ALDH1A1 2665/4885 |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | TDP1 3811/4885ERN1 2382/4885ALDH1A1 1545/4885 |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | TDP1 3811/4885ERN1 2382/4885ALDH1A1 1545/4885 |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HTR2A, HTR3A, HTR1A | TDP1 1593/4885ERN1 4125/4885ALDH1A1 1112/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | TDP1 3674/4885ERN1 2993/4885ALDH1A1 2665/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | TDP1 3674/4885ERN1 2993/4885ALDH1A1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.